Financial Data and Key Metrics Changes - The company reported third quarter revenue of $4.1 billion, reflecting a year-over-year growth of 5.2% on a reported basis and 3.9% at constant currency [16] - Adjusted EBITDA for the quarter was $949 million, representing a growth of 1.1% [17] - Third quarter adjusted diluted EPS was $3, an increase of 5.6% year over year [18] - Free cash flow reached a record high of $772 million for the quarter [19] Business Line Data and Key Metrics Changes - Technology and Analytics Solutions (TASS) revenue for the third quarter was $1.631 billion, up 5% reported and 3.3% at constant currency [16] - R&D Solutions revenue was $2.26 billion, growing 4.5% reported and 3.4% at constant currency [16] - Contract Sales and Medical Solutions (CSMS) revenue was $209 million, up 16.1% reported and 13.9% at constant currency [16] Market Data and Key Metrics Changes - Net bookings in the quarter totaled $2.6 billion, resulting in a net book-to-bill ratio of 1.15, with bookings up 13% year over year [22] - The backlog reached a record of $32.4 billion, showing growth of 4.1% compared to the prior year [18] - Biotech funding momentum reached $18 billion in Q3, indicating strong demand in the sector [6] Company Strategy and Development Direction - The company is focusing on expanding capabilities in Contract Sales and Medical Solutions, responding to a trend of large pharma clients outsourcing commercial operations [8] - The "see more, win more" strategy has been implemented to capture market segments previously overlooked, leading to improved RFP flows and bookings [26] - The company is investing in AI capabilities, with plans to develop 500 specialized AI agents by early 2027 to enhance operational efficiency and client service [99] Management's Comments on Operating Environment and Future Outlook - Management noted an improved industry backdrop and a reduction in market uncertainty, contributing to stronger client decision-making and demand [25] - The company reaffirmed its full-year 2025 guidance, expecting revenue growth of 4.8% to 5.5% [20] - Management expressed confidence that revenue growth in 2026 would be at least the same or better than the current year [32] Other Important Information - The CFO transition was announced, with Mike Fedock set to succeed Ron Bruehlman in February 2026 [13] - The company is seeing growing demand for phase one trials, indicating a shift in its operational focus [86] Q&A Session Summary Question: About the "see more, win more" strategy and its impact on RFP flows - Management indicated that the strategy has led to improved bookings momentum and a reduction in pricing competition, with a strong backlog supporting future revenue [25][27] Question: Expectations for business momentum into 2026 - Management refrained from providing specific guidance for 2026 but expressed confidence in maintaining or exceeding current growth rates [31][32] Question: Differences in performance between pharma and biotech segments - Management noted that large pharma has completed internal reprioritization, leading to stronger RFP flows and a healthier business environment [39] Question: Contributions from inorganic advancements in TASS - Management highlighted that most inorganic contributions are expected to come from TASS, with ongoing efforts to acquire technology companies to enhance capabilities [43][45] Question: Status of mega trials and their impact on guidance - Management confirmed that there are no changes to guidance due to the status of mega trials, which have been pushed out and are not factored into current revenue expectations [90][92] Question: Insights on AI's impact on customer business models and internal efficiencies - Management discussed the development of AI agents to improve operational efficiency and the potential for margin improvements in the long term [99][103]